HER2 Positive BC - A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

This is an open-label, Phase 2 study that will investigate the incidence of diarrhea in HER2+ breast cancer patients receiving neratinib with intensive high dose loperamide diarrhea prophylaxis who have previously undergone a course of trastuzumab therapy in the adjuvant setting.

See detailed information including eligibility.

2/2015
10/2016
NCT02400476
Cancer, Adult Breast Cancer
Accepting Participants
Interventional
2